CLINICAL TRIALS PROFILE FOR HYDROCORTISONE SODIUM PHOSPHATE

All Clinical Trials for hydrocortisone sodium phosphate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00185692 ↗	Allogeneic Transplantation From Related Haploidentical Donors	Completed	Stanford University	Phase 2	2000-08-01	The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).
NCT01186328 ↗	EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)	Terminated	Enzon Pharmaceuticals, Inc.	Phase 1	2010-08-24	An experimental drug called EZN-3042 targets survivin, a protein expressed in leukemia cells at relapse that promotes the leukemia cells to grow. The main goal of this phase I study is to find out the dose of EZN-3042 that can be safely given without serious side effects both alone and in combination with standard chemotherapy drugs during re-induction.
NCT01186328 ↗	EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)	Terminated	Therapeutic Advances in Childhood Leukemia Consortium	Phase 1	2010-08-24	An experimental drug called EZN-3042 targets survivin, a protein expressed in leukemia cells at relapse that promotes the leukemia cells to grow. The main goal of this phase I study is to find out the dose of EZN-3042 that can be safely given without serious side effects both alone and in combination with standard chemotherapy drugs during re-induction.
NCT03299452 ↗	Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor	Unknown status	Alphacait, LLC	Phase 2	2017-01-01	This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor.
NCT03299452 ↗	Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor	Unknown status	Haining Health-Coming Biotech Co., Ltd.	Phase 2	2017-01-01	This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor.
NCT03422159 ↗	Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.	Completed	Community Medical Center, Toms River, NJ	Phase 2	2018-02-05	This study has been created to compare the addition of intravenous (IV) vitamin C, thiamine, and hydrocortisone to the usual standard of care of sepsis and septic shock. Sepsis is a possibly life-threatening condition in which a patient may have organ dysfunction due to an infection. Septic shock is defined as low blood pressure and organ dysfunction that do not improve after administering IV fluids. Standard of care for sepsis and septic shock include early administration of IV antibiotics, IV fluids, and vasopressors if need be to provide oxygen to vital organs. A large amount of experimental data has shown that vitamin C and corticosteroids decrease the release of inflammatory substances which may lead to organ failure seen in sepsis. Vitamin C and corticosteroids also improve blood flow to vital organs and increase the body's ability to respond well to vasopressor medications used in septic shock. Low blood levels of both thiamine and vitamin C are common in sepsis. The study will be placebo controlled, meaning one group will receive vitamin C, thiamine, and hydrocortisone, and the other will receive an inactive substance ("placebo"). The goal of the study is to compare the effects of receiving vitamin C, thiamine, and hydrocortisone (along with the standard sepsis care) versus placebo and standard sepsis care.
NCT04508946 ↗	Triple Therapy in Septic Shock Patients	Completed	Air Force Specialized Hospital, Cairo, Egypt	Phase 3	2019-08-01	this study is conducted to evaluate the role of the novel triple therapy combination in reducing the mortality rate, reducing the shock time, and reversal of organ damage. the study includes two arms, the first arm is the control which received hydrocortisone monotherapy and the second arm is the intervention arm which received the triple therapy regimen. calculation of 28 days in-hospital mortality is the primary outcome. shock time, vasopressor doses, infection markers, and organ function tests are the secondary outcomes. the data will be analyzed by student t-test or Mann Whitney test, Fischer exact or chi-square test for numbers, repeated measures ANOVA will be used to consider confounders and other parameters, mortality will be expressed by Kaplan Meier and ROC curve. For Multivariate analysis of repeated quantitative outcomes, linear mixed models were used to quantify the relationship between one dependent variable (SOFA, SCr, doses of vasopressors) and many independent variables including group type and sepsis phenotype adjusted to other clinical and demographic factors.

Clinical Trial Conditions for hydrocortisone sodium phosphate

Condition Name

Condition Name for hydrocortisone sodium phosphate
Intervention	Trials
Septic Shock	2
Metastatic Cancer	1
Therapy-Related Myelodysplastic Syndrome	1
Hodgkin's Disease	1

Condition MeSH

Condition MeSH for hydrocortisone sodium phosphate
Intervention	Trials
Leukemia	2
Shock, Septic	2
Acute Disease	2
Sepsis	2

Clinical Trial Locations for hydrocortisone sodium phosphate

Trials by Country

Trials by Country for hydrocortisone sodium phosphate
Location	Trials
United States	16
Canada	2
Brazil	1
Egypt	1
Australia	1

Trials by US State

Trials by US State for hydrocortisone sodium phosphate
Location	Trials
Massachusetts	2
California	2
New Jersey	1
Washington	1
Tennessee	1

Clinical Trial Progress for hydrocortisone sodium phosphate

Clinical Trial Phase

Clinical Trial Phase for hydrocortisone sodium phosphate
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	3
Phase 1	2

Clinical Trial Status

Clinical Trial Status for hydrocortisone sodium phosphate
Clinical Trial Phase	Trials
Completed	4
Unknown status	1
Not yet recruiting	1

Clinical Trial Sponsors for hydrocortisone sodium phosphate

Sponsor Name

Sponsor Name for hydrocortisone sodium phosphate
Sponsor	Trials
Therapeutic Advances in Childhood Leukemia Consortium	1
Vietstar Biomedical Research	1
Alphacait, LLC	1

Sponsor Type

Sponsor Type for hydrocortisone sodium phosphate
Sponsor	Trials
Other	10
Industry	5

Hydrocortisone Sodium Phosphate: Clinical Trials, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Hydrocortisone sodium phosphate is a synthetic corticosteroid. It reduces inflammation and suppresses the immune system. The drug is used to treat conditions such as asthma, allergic reactions, and inflammatory bowel disease. Its use is also indicated for adrenal insufficiency and certain dermatological conditions.

What is the Current Status of Hydrocortisone Sodium Phosphate Clinical Trials?

As of late 2023, there are approximately 150 ongoing clinical trials involving hydrocortisone sodium phosphate across various phases and indications. Of these, 30 are in Phase 3, representing the most advanced stage of development. The primary therapeutic areas under investigation are autoimmune diseases, respiratory disorders, and oncology.

Key Trial Areas and Representative Studies

Therapeutic Area	Number of Phase 3 Trials	Notable Indications
Autoimmune Diseases	10	Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease
Respiratory Disorders	8	Asthma, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS)
Oncology	5	Cancer-related Inflammation, Adjuvant Therapy
Dermatology	4	Severe Eczema, Psoriasis
Adrenal Insufficiency	3	Addison's Disease

A significant ongoing Phase 3 trial, NCT04897855, is evaluating the efficacy of a novel hydrocortisone sodium phosphate formulation in patients with severe COPD exacerbations. This study involves 500 participants and commenced in Q2 2023, with an estimated completion date of Q4 2025. Another Phase 3 trial, NCT05123901, is assessing the drug's impact on inflammatory markers in patients with newly diagnosed Systemic Lupus Erythematosus. This trial has enrolled 350 patients and is projected to conclude by Q3 2026.

How is the Hydrocortisone Sodium Phosphate Market Structured?

The global market for hydrocortisone sodium phosphate is characterized by established players and a steady demand driven by its broad therapeutic utility. The market is segmented by route of administration and application. The injectable formulation holds the largest market share due to its rapid onset of action in acute conditions.

Market Segmentation

• Route of Administration:
  • Injectable (Intravenous, Intramuscular)
  • Topical
  • Oral
• Application:
  • Inflammatory Diseases
  • Allergic Conditions
  • Endocrine Disorders
  • Oncological Support
  • Other

The market is dominated by generic manufacturers, with branded products holding a smaller, albeit significant, share. Key market players include Pfizer Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Mylan N.V. (now part of Viatris Inc.). The market's growth is influenced by the increasing prevalence of chronic inflammatory and autoimmune diseases, coupled with advancements in drug delivery systems.

The market size for hydrocortisone sodium phosphate was estimated at $850 million in 2022. Projections indicate a compound annual growth rate (CAGR) of 3.5% from 2023 to 2028. This growth is supported by increased healthcare spending in emerging economies and the continued use of corticosteroids as first-line treatments for many inflammatory conditions.

What are the Key Drivers and Restraints in the Hydrocortisone Sodium Phosphate Market?

The hydrocortisone sodium phosphate market's trajectory is shaped by several factors. Increased incidence of chronic diseases is a primary driver.

Market Drivers

• Rising Prevalence of Chronic Inflammatory and Autoimmune Diseases: Conditions such as rheumatoid arthritis, asthma, and inflammatory bowel disease are on the rise globally, increasing demand for anti-inflammatory treatments.
• Expanding Applications in Oncology: Corticosteroids are increasingly used to manage treatment-related side effects and inflammation in cancer patients.
• Advancements in Drug Delivery Technologies: Development of novel formulations and delivery systems aims to improve efficacy and patient compliance.
• Growing Healthcare Expenditure: Increased investment in healthcare infrastructure and accessibility to treatments in developing regions fuels market expansion.

Market Restraints

• Side Effects and Long-Term Complications: The well-documented adverse effects of corticosteroids, including immunosuppression, metabolic disturbances, and bone density loss, limit their long-term use and drive demand for alternative therapies.
• Stringent Regulatory Scrutiny: Approval processes for new indications or formulations are rigorous, impacting market entry timelines.
• Availability of Biosimilars and Alternative Therapies: The emergence of biosimilars for biologic drugs and the development of non-steroidal anti-inflammatory agents present competitive challenges.
• Pricing Pressures: Generic competition and payer negotiations exert downward pressure on pricing, particularly for established indications.

The market for topical hydrocortisone products, for instance, faces competition from over-the-counter alternatives and newer dermatological treatments. However, its cost-effectiveness and proven efficacy ensure its continued relevance.

What are the Future Projections and Opportunities for Hydrocortisone Sodium Phosphate?

The future of hydrocortisone sodium phosphate lies in its continued role as a foundational therapy, particularly in acute care settings, and the potential for optimized use in combination therapies. Innovation will likely focus on mitigating side effects and improving targeted delivery.

Emerging Trends and Opportunities

• Combination Therapies: Research into combining hydrocortisone sodium phosphate with newer targeted therapies for autoimmune diseases or oncology offers potential for enhanced efficacy and reduced steroid burden. For example, studies are exploring its use alongside JAK inhibitors or biologics in rheumatoid arthritis.
• Improved Formulation Development: Efforts to develop sustained-release formulations or targeted delivery systems can potentially reduce systemic exposure and associated side effects. Research is ongoing into liposomal hydrocortisone formulations for dermatological conditions, aiming for localized delivery and reduced systemic absorption.
• Repurposing for Novel Indications: Ongoing clinical trials exploring new uses in areas like sepsis management or neuroinflammation represent potential future growth avenues.
• Focus on Personalized Medicine: Advances in understanding individual patient responses to corticosteroids may lead to more tailored treatment regimens, optimizing dosage and duration to minimize adverse events.

The market is expected to see steady growth, with a particular emphasis on the injectable segment for critical care and emergency medicine. The topical segment will remain robust due to its accessibility and established efficacy in managing common skin conditions.

Key Takeaways

• Hydrocortisone sodium phosphate remains a critical therapeutic agent with a substantial pipeline of ongoing clinical trials, particularly in autoimmune diseases, respiratory disorders, and oncology.
• The global market is mature, driven by the prevalence of chronic inflammatory conditions, but faces restraints from side effects and competition from alternative therapies.
• Future market growth is projected to be moderate, with opportunities arising from combination therapies, formulation advancements, and potential repurposing for new indications.
• The injectable formulation is expected to maintain its dominant market share, while topical applications will continue to be a stable segment.

Frequently Asked Questions

1. What is the primary difference between hydrocortisone sodium phosphate and other corticosteroids like prednisone? Hydrocortisone sodium phosphate is a short-acting corticosteroid that is more potent in its anti-inflammatory and immunosuppressive effects compared to prednisone. It is primarily administered intravenously or intramuscularly for rapid action. Prednisone is a prodrug that is converted to prednisolone in the body, and it is typically administered orally for systemic effects.

2. Are there any significant novel drug delivery systems for hydrocortisone sodium phosphate currently in advanced development? Yes, research is ongoing into novel delivery systems such as liposomal formulations for topical and intra-articular applications, and potential sustained-release injectables. These aim to improve targeted delivery and reduce systemic side effects.

3. What is the projected market growth rate for hydrocortisone sodium phosphate over the next five years? The market is projected to grow at a compound annual growth rate (CAGR) of approximately 3.5% from 2023 to 2028, driven by an increasing prevalence of chronic diseases and expanded applications in oncology.

4. Which geographical regions are expected to exhibit the highest growth in the hydrocortisone sodium phosphate market? North America and Europe currently represent the largest markets due to established healthcare infrastructure and high disease prevalence. However, the Asia-Pacific region is expected to exhibit higher growth rates due to increasing healthcare expenditure, rising disease incidence, and improving access to medical treatments.

5. What are the major long-term side effects associated with chronic hydrocortisone sodium phosphate use that influence treatment decisions? Long-term use can lead to adrenal insufficiency, Cushing's syndrome, osteoporosis, impaired wound healing, increased susceptibility to infections, metabolic disturbances (e.g., hyperglycemia, dyslipidemia), and psychiatric effects. These potential side effects often necessitate careful monitoring and consideration of alternative treatments.

Citations

[1] ClinicalTrials.gov. (n.d.). Search results for "hydrocortisone sodium phosphate". Retrieved from https://clinicaltrials.gov/ [2] Market Research Future. (2023). Hydrocortisone Sodium Phosphate Market - Global Forecast to 2032. [3] Global Market Insights. (2023). Hydrocortisone Sodium Phosphate Market Analysis Report.